Brokerages predict that AnaptysBio, Inc. (NASDAQ:ANAB) will report ($0.47) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for AnaptysBio’s earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.48). The firm is scheduled to issue its next quarterly earnings report on Thursday, August 10th.
Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover AnaptysBio.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.57.
Several research firms recently issued reports on ANAB. Stifel Nicolaus began coverage on shares of AnaptysBio in a report on Tuesday, February 21st. They issued a “buy” rating and a $30.00 target price on the stock. JMP Securities restated an “outperform” rating and issued a $45.00 target price on shares of AnaptysBio in a report on Friday, March 31st. Credit Suisse Group restated an “outperform” rating and issued a $34.00 target price on shares of AnaptysBio in a report on Tuesday, April 18th. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of AnaptysBio in a report on Monday, March 6th. Finally, Zacks Investment Research lowered shares of AnaptysBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $35.50.
Shares of AnaptysBio (NASDAQ ANAB) traded up 1.37% during mid-day trading on Tuesday, reaching $23.72. The company had a trading volume of 100,985 shares. AnaptysBio has a one year low of $15.17 and a one year high of $29.96. The firm’s market capitalization is $480.78 million. The stock has a 50 day moving average of $25.17 and a 200-day moving average of $24.37.
COPYRIGHT VIOLATION WARNING: This report was originally published by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://sleekmoney.com/0-47-earnings-per-share-expected-for-anaptysbio-inc-anab-this-quarter/1916650.html.
Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE bought a new position in shares of AnaptysBio during the first quarter valued at $123,000. Teachers Advisors LLC bought a new position in shares of AnaptysBio during the first quarter valued at $214,000. TIAA CREF Investment Management LLC bought a new position in shares of AnaptysBio during the first quarter valued at $227,000. Endurant Capital Management LP bought a new position in shares of AnaptysBio during the first quarter valued at $258,000. Finally, Morgan Stanley bought a new position in shares of AnaptysBio during the first quarter valued at $310,000. Hedge funds and other institutional investors own 72.59% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/0-47-earnings-per-share-expected-for-anaptysbio-inc-anab-this-quarter/1916650.html
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.